Nimotuzumab
| Nimotuzumab?
| |
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | EGFR |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C6566H10082N1746O2056S40 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Nimotuzumab | |
|
Articles | |
|---|---|
|
Most recent articles on Nimotuzumab Most cited articles on Nimotuzumab | |
|
Media | |
|
Powerpoint slides on Nimotuzumab | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Nimotuzumab at Clinical Trials.gov Clinical Trials on Nimotuzumab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Nimotuzumab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Nimotuzumab Discussion groups on Nimotuzumab Patient Handouts on Nimotuzumab Directions to Hospitals Treating Nimotuzumab Risk calculators and risk factors for Nimotuzumab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Nimotuzumab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Nimotuzumab is a humanized monoclonal antibody used to treat cancer. It binds to EGFR (epithelial growth factor receptor).
Humanized monoclonal antibodies ("-zu-") | |
|---|---|
| "-tuzu-" (tumor) | Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin |
| "-lizu-" (immune system) | Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab |
| "-bazu-" (bacterial) | Tefibazumab |
| "-cizu-" (cardiovascular) | Bevacizumab, Tadocizumab |
| "-neuzu-" (nervous system) | Bapineuzumab |
| "-toxazu-" (toxin as target) | Urtoxazumab |
| "-vizu-" (viral infections) | Felvizumab, Motavizumab, Palivizumab, PRO 140 |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
